Global Inactivated Vaccine Market Research Report 2025(Status and Outlook)
Report Overview
The inactivated vaccine market involves vaccines produced by killing the disease-causing microorganism (virus or bacteria) through chemical, heat, or radiation methods, rendering it non-infectious while retaining its ability to stimulate an immune response. These vaccines are widely used due to their safety profile, as they cannot cause the disease they protect against, making them suitable for immunocompromised individuals. Key applications include polio (IPV), rabies, hepatitis A, and influenza vaccines. The market is driven by increasing immunization programs, government support for vaccine development, and rising awareness of infectious diseases. However, challenges include the need for multiple doses to maintain immunity and higher production costs compared to live-attenuated vaccines. Major players include Sanofi, GSK, and Sinovac, with growing demand in emerging markets due to expanding healthcare infrastructure and pandemic preparedness initiatives. The COVID-19 pandemic further accelerated interest in inactivated vaccine platforms, reinforcing their role in global immunization strategies.
The global Inactivated Vaccine market size was estimated at USD 6621.47 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.33% during the forecast period.
This report provides a deep insight into the global Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine market in any manner.
Global Inactivated Vaccine Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson and Johnson (U.S.)
MedImmune (U.S.)
Merck and Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)
Market Segmentation (by Type)
Children
Adult
Market Segmentation (by Application)
Hospital
Medical Center
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Inactivated Vaccine Market
Overview of the regional outlook of the Inactivated Vaccine Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Inactivated Vaccine, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The inactivated vaccine market involves vaccines produced by killing the disease-causing microorganism (virus or bacteria) through chemical, heat, or radiation methods, rendering it non-infectious while retaining its ability to stimulate an immune response. These vaccines are widely used due to their safety profile, as they cannot cause the disease they protect against, making them suitable for immunocompromised individuals. Key applications include polio (IPV), rabies, hepatitis A, and influenza vaccines. The market is driven by increasing immunization programs, government support for vaccine development, and rising awareness of infectious diseases. However, challenges include the need for multiple doses to maintain immunity and higher production costs compared to live-attenuated vaccines. Major players include Sanofi, GSK, and Sinovac, with growing demand in emerging markets due to expanding healthcare infrastructure and pandemic preparedness initiatives. The COVID-19 pandemic further accelerated interest in inactivated vaccine platforms, reinforcing their role in global immunization strategies.
The global Inactivated Vaccine market size was estimated at USD 6621.47 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.33% during the forecast period.
This report provides a deep insight into the global Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine market in any manner.
Global Inactivated Vaccine Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson and Johnson (U.S.)
MedImmune (U.S.)
Merck and Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)
Market Segmentation (by Type)
Children
Adult
Market Segmentation (by Application)
Hospital
Medical Center
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Inactivated Vaccine Market
Overview of the regional outlook of the Inactivated Vaccine Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Inactivated Vaccine, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Inactivated Vaccine
1.2 Key Market Segments
1.2.1 Inactivated Vaccine Segment by Type
1.2.2 Inactivated Vaccine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INACTIVATED VACCINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Inactivated Vaccine Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Inactivated Vaccine Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Inactivated Vaccine Product Life Cycle
3.3 Global Inactivated Vaccine Sales by Manufacturers (2020-2025)
3.4 Global Inactivated Vaccine Revenue Market Share by Manufacturers (2020-2025)
3.5 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Inactivated Vaccine Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Inactivated Vaccine Market Competitive Situation and Trends
3.8.1 Inactivated Vaccine Market Concentration Rate
3.8.2 Global 5 and 10 Largest Inactivated Vaccine Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE INDUSTRY CHAIN ANALYSIS
4.1 Inactivated Vaccine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INACTIVATED VACCINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Inactivated Vaccine Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Inactivated Vaccine Market
5.7 ESG Ratings of Leading Companies
6 INACTIVATED VACCINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine Sales Market Share by Type (2020-2025)
6.3 Global Inactivated Vaccine Market Size Market Share by Type (2020-2025)
6.4 Global Inactivated Vaccine Price by Type (2020-2025)
7 INACTIVATED VACCINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine Market Sales by Application (2020-2025)
7.3 Global Inactivated Vaccine Market Size (M USD) by Application (2020-2025)
7.4 Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
8 INACTIVATED VACCINE MARKET SALES BY REGION
8.1 Global Inactivated Vaccine Sales by Region
8.1.1 Global Inactivated Vaccine Sales by Region
8.1.2 Global Inactivated Vaccine Sales Market Share by Region
8.2 Global Inactivated Vaccine Market Size by Region
8.2.1 Global Inactivated Vaccine Market Size by Region
8.2.2 Global Inactivated Vaccine Market Size Market Share by Region
8.3 North America
8.3.1 North America Inactivated Vaccine Sales by Country
8.3.2 North America Inactivated Vaccine Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Inactivated Vaccine Sales by Country
8.4.2 Europe Inactivated Vaccine Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Inactivated Vaccine Sales by Region
8.5.2 Asia Pacific Inactivated Vaccine Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Inactivated Vaccine Sales by Country
8.6.2 South America Inactivated Vaccine Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Inactivated Vaccine Sales by Region
8.7.2 Middle East and Africa Inactivated Vaccine Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 INACTIVATED VACCINE MARKET PRODUCTION BY REGION
9.1 Global Production of Inactivated Vaccine by Region(2020-2025)
9.2 Global Inactivated Vaccine Revenue Market Share by Region (2020-2025)
9.3 Global Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Inactivated Vaccine Production
9.4.1 North America Inactivated Vaccine Production Growth Rate (2020-2025)
9.4.2 North America Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Inactivated Vaccine Production
9.5.1 Europe Inactivated Vaccine Production Growth Rate (2020-2025)
9.5.2 Europe Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Inactivated Vaccine Production (2020-2025)
9.6.1 Japan Inactivated Vaccine Production Growth Rate (2020-2025)
9.6.2 Japan Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Inactivated Vaccine Production (2020-2025)
9.7.1 China Inactivated Vaccine Production Growth Rate (2020-2025)
9.7.2 China Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Astellas Pharma (Japan)
10.1.1 Astellas Pharma (Japan) Basic Information
10.1.2 Astellas Pharma (Japan) Inactivated Vaccine Product Overview
10.1.3 Astellas Pharma (Japan) Inactivated Vaccine Product Market Performance
10.1.4 Astellas Pharma (Japan) Business Overview
10.1.5 Astellas Pharma (Japan) SWOT Analysis
10.1.6 Astellas Pharma (Japan) Recent Developments
10.2 CSL Limited (Australia)
10.2.1 CSL Limited (Australia) Basic Information
10.2.2 CSL Limited (Australia) Inactivated Vaccine Product Overview
10.2.3 CSL Limited (Australia) Inactivated Vaccine Product Market Performance
10.2.4 CSL Limited (Australia) Business Overview
10.2.5 CSL Limited (Australia) SWOT Analysis
10.2.6 CSL Limited (Australia) Recent Developments
10.3 Emergent BioSolutions (U.S.)
10.3.1 Emergent BioSolutions (U.S.) Basic Information
10.3.2 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
10.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Market Performance
10.3.4 Emergent BioSolutions (U.S.) Business Overview
10.3.5 Emergent BioSolutions (U.S.) SWOT Analysis
10.3.6 Emergent BioSolutions (U.S.) Recent Developments
10.4 GlaxoSmithKline (U.K.)
10.4.1 GlaxoSmithKline (U.K.) Basic Information
10.4.2 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
10.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Market Performance
10.4.4 GlaxoSmithKline (U.K.) Business Overview
10.4.5 GlaxoSmithKline (U.K.) Recent Developments
10.5 Johnson and Johnson (U.S.)
10.5.1 Johnson and Johnson (U.S.) Basic Information
10.5.2 Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
10.5.3 Johnson and Johnson (U.S.) Inactivated Vaccine Product Market Performance
10.5.4 Johnson and Johnson (U.S.) Business Overview
10.5.5 Johnson and Johnson (U.S.) Recent Developments
10.6 MedImmune (U.S.)
10.6.1 MedImmune (U.S.) Basic Information
10.6.2 MedImmune (U.S.) Inactivated Vaccine Product Overview
10.6.3 MedImmune (U.S.) Inactivated Vaccine Product Market Performance
10.6.4 MedImmune (U.S.) Business Overview
10.6.5 MedImmune (U.S.) Recent Developments
10.7 Merck and Co (U.S.)
10.7.1 Merck and Co (U.S.) Basic Information
10.7.2 Merck and Co (U.S.) Inactivated Vaccine Product Overview
10.7.3 Merck and Co (U.S.) Inactivated Vaccine Product Market Performance
10.7.4 Merck and Co (U.S.) Business Overview
10.7.5 Merck and Co (U.S.) Recent Developments
10.8 Pfizer (U.S.)
10.8.1 Pfizer (U.S.) Basic Information
10.8.2 Pfizer (U.S.) Inactivated Vaccine Product Overview
10.8.3 Pfizer (U.S.) Inactivated Vaccine Product Market Performance
10.8.4 Pfizer (U.S.) Business Overview
10.8.5 Pfizer (U.S.) Recent Developments
10.9 Sanofi Pasteur (France)
10.9.1 Sanofi Pasteur (France) Basic Information
10.9.2 Sanofi Pasteur (France) Inactivated Vaccine Product Overview
10.9.3 Sanofi Pasteur (France) Inactivated Vaccine Product Market Performance
10.9.4 Sanofi Pasteur (France) Business Overview
10.9.5 Sanofi Pasteur (France) Recent Developments
10.10 Serum Institute of India Pvt (India)
10.10.1 Serum Institute of India Pvt (India) Basic Information
10.10.2 Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
10.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Product Market Performance
10.10.4 Serum Institute of India Pvt (India) Business Overview
10.10.5 Serum Institute of India Pvt (India) Recent Developments
11 INACTIVATED VACCINE MARKET FORECAST BY REGION
11.1 Global Inactivated Vaccine Market Size Forecast
11.2 Global Inactivated Vaccine Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Inactivated Vaccine Market Size Forecast by Country
11.2.3 Asia Pacific Inactivated Vaccine Market Size Forecast by Region
11.2.4 South America Inactivated Vaccine Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Inactivated Vaccine by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Inactivated Vaccine Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Inactivated Vaccine by Type (2026-2033)
12.1.2 Global Inactivated Vaccine Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Inactivated Vaccine by Type (2026-2033)
12.2 Global Inactivated Vaccine Market Forecast by Application (2026-2033)
12.2.1 Global Inactivated Vaccine Sales (K MT) Forecast by Application
12.2.2 Global Inactivated Vaccine Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Inactivated Vaccine
1.2 Key Market Segments
1.2.1 Inactivated Vaccine Segment by Type
1.2.2 Inactivated Vaccine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INACTIVATED VACCINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Inactivated Vaccine Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Inactivated Vaccine Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Inactivated Vaccine Product Life Cycle
3.3 Global Inactivated Vaccine Sales by Manufacturers (2020-2025)
3.4 Global Inactivated Vaccine Revenue Market Share by Manufacturers (2020-2025)
3.5 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Inactivated Vaccine Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Inactivated Vaccine Market Competitive Situation and Trends
3.8.1 Inactivated Vaccine Market Concentration Rate
3.8.2 Global 5 and 10 Largest Inactivated Vaccine Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE INDUSTRY CHAIN ANALYSIS
4.1 Inactivated Vaccine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INACTIVATED VACCINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Inactivated Vaccine Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Inactivated Vaccine Market
5.7 ESG Ratings of Leading Companies
6 INACTIVATED VACCINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine Sales Market Share by Type (2020-2025)
6.3 Global Inactivated Vaccine Market Size Market Share by Type (2020-2025)
6.4 Global Inactivated Vaccine Price by Type (2020-2025)
7 INACTIVATED VACCINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine Market Sales by Application (2020-2025)
7.3 Global Inactivated Vaccine Market Size (M USD) by Application (2020-2025)
7.4 Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
8 INACTIVATED VACCINE MARKET SALES BY REGION
8.1 Global Inactivated Vaccine Sales by Region
8.1.1 Global Inactivated Vaccine Sales by Region
8.1.2 Global Inactivated Vaccine Sales Market Share by Region
8.2 Global Inactivated Vaccine Market Size by Region
8.2.1 Global Inactivated Vaccine Market Size by Region
8.2.2 Global Inactivated Vaccine Market Size Market Share by Region
8.3 North America
8.3.1 North America Inactivated Vaccine Sales by Country
8.3.2 North America Inactivated Vaccine Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Inactivated Vaccine Sales by Country
8.4.2 Europe Inactivated Vaccine Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Inactivated Vaccine Sales by Region
8.5.2 Asia Pacific Inactivated Vaccine Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Inactivated Vaccine Sales by Country
8.6.2 South America Inactivated Vaccine Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Inactivated Vaccine Sales by Region
8.7.2 Middle East and Africa Inactivated Vaccine Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 INACTIVATED VACCINE MARKET PRODUCTION BY REGION
9.1 Global Production of Inactivated Vaccine by Region(2020-2025)
9.2 Global Inactivated Vaccine Revenue Market Share by Region (2020-2025)
9.3 Global Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Inactivated Vaccine Production
9.4.1 North America Inactivated Vaccine Production Growth Rate (2020-2025)
9.4.2 North America Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Inactivated Vaccine Production
9.5.1 Europe Inactivated Vaccine Production Growth Rate (2020-2025)
9.5.2 Europe Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Inactivated Vaccine Production (2020-2025)
9.6.1 Japan Inactivated Vaccine Production Growth Rate (2020-2025)
9.6.2 Japan Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Inactivated Vaccine Production (2020-2025)
9.7.1 China Inactivated Vaccine Production Growth Rate (2020-2025)
9.7.2 China Inactivated Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Astellas Pharma (Japan)
10.1.1 Astellas Pharma (Japan) Basic Information
10.1.2 Astellas Pharma (Japan) Inactivated Vaccine Product Overview
10.1.3 Astellas Pharma (Japan) Inactivated Vaccine Product Market Performance
10.1.4 Astellas Pharma (Japan) Business Overview
10.1.5 Astellas Pharma (Japan) SWOT Analysis
10.1.6 Astellas Pharma (Japan) Recent Developments
10.2 CSL Limited (Australia)
10.2.1 CSL Limited (Australia) Basic Information
10.2.2 CSL Limited (Australia) Inactivated Vaccine Product Overview
10.2.3 CSL Limited (Australia) Inactivated Vaccine Product Market Performance
10.2.4 CSL Limited (Australia) Business Overview
10.2.5 CSL Limited (Australia) SWOT Analysis
10.2.6 CSL Limited (Australia) Recent Developments
10.3 Emergent BioSolutions (U.S.)
10.3.1 Emergent BioSolutions (U.S.) Basic Information
10.3.2 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
10.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Market Performance
10.3.4 Emergent BioSolutions (U.S.) Business Overview
10.3.5 Emergent BioSolutions (U.S.) SWOT Analysis
10.3.6 Emergent BioSolutions (U.S.) Recent Developments
10.4 GlaxoSmithKline (U.K.)
10.4.1 GlaxoSmithKline (U.K.) Basic Information
10.4.2 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
10.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Market Performance
10.4.4 GlaxoSmithKline (U.K.) Business Overview
10.4.5 GlaxoSmithKline (U.K.) Recent Developments
10.5 Johnson and Johnson (U.S.)
10.5.1 Johnson and Johnson (U.S.) Basic Information
10.5.2 Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
10.5.3 Johnson and Johnson (U.S.) Inactivated Vaccine Product Market Performance
10.5.4 Johnson and Johnson (U.S.) Business Overview
10.5.5 Johnson and Johnson (U.S.) Recent Developments
10.6 MedImmune (U.S.)
10.6.1 MedImmune (U.S.) Basic Information
10.6.2 MedImmune (U.S.) Inactivated Vaccine Product Overview
10.6.3 MedImmune (U.S.) Inactivated Vaccine Product Market Performance
10.6.4 MedImmune (U.S.) Business Overview
10.6.5 MedImmune (U.S.) Recent Developments
10.7 Merck and Co (U.S.)
10.7.1 Merck and Co (U.S.) Basic Information
10.7.2 Merck and Co (U.S.) Inactivated Vaccine Product Overview
10.7.3 Merck and Co (U.S.) Inactivated Vaccine Product Market Performance
10.7.4 Merck and Co (U.S.) Business Overview
10.7.5 Merck and Co (U.S.) Recent Developments
10.8 Pfizer (U.S.)
10.8.1 Pfizer (U.S.) Basic Information
10.8.2 Pfizer (U.S.) Inactivated Vaccine Product Overview
10.8.3 Pfizer (U.S.) Inactivated Vaccine Product Market Performance
10.8.4 Pfizer (U.S.) Business Overview
10.8.5 Pfizer (U.S.) Recent Developments
10.9 Sanofi Pasteur (France)
10.9.1 Sanofi Pasteur (France) Basic Information
10.9.2 Sanofi Pasteur (France) Inactivated Vaccine Product Overview
10.9.3 Sanofi Pasteur (France) Inactivated Vaccine Product Market Performance
10.9.4 Sanofi Pasteur (France) Business Overview
10.9.5 Sanofi Pasteur (France) Recent Developments
10.10 Serum Institute of India Pvt (India)
10.10.1 Serum Institute of India Pvt (India) Basic Information
10.10.2 Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
10.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Product Market Performance
10.10.4 Serum Institute of India Pvt (India) Business Overview
10.10.5 Serum Institute of India Pvt (India) Recent Developments
11 INACTIVATED VACCINE MARKET FORECAST BY REGION
11.1 Global Inactivated Vaccine Market Size Forecast
11.2 Global Inactivated Vaccine Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Inactivated Vaccine Market Size Forecast by Country
11.2.3 Asia Pacific Inactivated Vaccine Market Size Forecast by Region
11.2.4 South America Inactivated Vaccine Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Inactivated Vaccine by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Inactivated Vaccine Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Inactivated Vaccine by Type (2026-2033)
12.1.2 Global Inactivated Vaccine Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Inactivated Vaccine by Type (2026-2033)
12.2 Global Inactivated Vaccine Market Forecast by Application (2026-2033)
12.2.1 Global Inactivated Vaccine Sales (K MT) Forecast by Application
12.2.2 Global Inactivated Vaccine Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine Market Size Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Inactivated Vaccine Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Inactivated Vaccine Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2024)
Table 10. Global Market Inactivated Vaccine Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Inactivated Vaccine Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Inactivated Vaccine Sales by Type (K MT)
Table 26. Global Inactivated Vaccine Market Size by Type (M USD)
Table 27. Global Inactivated Vaccine Sales (K MT) by Type (2020-2025)
Table 28. Global Inactivated Vaccine Sales Market Share by Type (2020-2025)
Table 29. Global Inactivated Vaccine Market Size (M USD) by Type (2020-2025)
Table 30. Global Inactivated Vaccine Market Size Share by Type (2020-2025)
Table 31. Global Inactivated Vaccine Price (USD/KG) by Type (2020-2025)
Table 32. Global Inactivated Vaccine Sales (K MT) by Application
Table 33. Global Inactivated Vaccine Market Size by Application
Table 34. Global Inactivated Vaccine Sales by Application (2020-2025) & (K MT)
Table 35. Global Inactivated Vaccine Sales Market Share by Application (2020-2025)
Table 36. Global Inactivated Vaccine Market Size by Application (2020-2025) & (M USD)
Table 37. Global Inactivated Vaccine Market Share by Application (2020-2025)
Table 38. Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
Table 39. Global Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 40. Global Inactivated Vaccine Sales Market Share by Region (2020-2025)
Table 41. Global Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 42. Global Inactivated Vaccine Market Size Market Share by Region (2020-2025)
Table 43. North America Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 44. North America Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 46. Europe Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 49. South America Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 50. South America Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 53. Global Inactivated Vaccine Production (K MT) by Region(2020-2025)
Table 54. Global Inactivated Vaccine Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Inactivated Vaccine Revenue Market Share by Region (2020-2025)
Table 56. Global Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Astellas Pharma (Japan) Basic Information
Table 62. Astellas Pharma (Japan) Inactivated Vaccine Product Overview
Table 63. Astellas Pharma (Japan) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Astellas Pharma (Japan) Business Overview
Table 65. Astellas Pharma (Japan) SWOT Analysis
Table 66. Astellas Pharma (Japan) Recent Developments
Table 67. CSL Limited (Australia) Basic Information
Table 68. CSL Limited (Australia) Inactivated Vaccine Product Overview
Table 69. CSL Limited (Australia) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. CSL Limited (Australia) Business Overview
Table 71. CSL Limited (Australia) SWOT Analysis
Table 72. CSL Limited (Australia) Recent Developments
Table 73. Emergent BioSolutions (U.S.) Basic Information
Table 74. Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
Table 75. Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Emergent BioSolutions (U.S.) Business Overview
Table 77. Emergent BioSolutions (U.S.) SWOT Analysis
Table 78. Emergent BioSolutions (U.S.) Recent Developments
Table 79. GlaxoSmithKline (U.K.) Basic Information
Table 80. GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
Table 81. GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. GlaxoSmithKline (U.K.) Business Overview
Table 83. GlaxoSmithKline (U.K.) Recent Developments
Table 84. Johnson and Johnson (U.S.) Basic Information
Table 85. Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
Table 86. Johnson and Johnson (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. Johnson and Johnson (U.S.) Business Overview
Table 88. Johnson and Johnson (U.S.) Recent Developments
Table 89. MedImmune (U.S.) Basic Information
Table 90. MedImmune (U.S.) Inactivated Vaccine Product Overview
Table 91. MedImmune (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. MedImmune (U.S.) Business Overview
Table 93. MedImmune (U.S.) Recent Developments
Table 94. Merck and Co (U.S.) Basic Information
Table 95. Merck and Co (U.S.) Inactivated Vaccine Product Overview
Table 96. Merck and Co (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Merck and Co (U.S.) Business Overview
Table 98. Merck and Co (U.S.) Recent Developments
Table 99. Pfizer (U.S.) Basic Information
Table 100. Pfizer (U.S.) Inactivated Vaccine Product Overview
Table 101. Pfizer (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Pfizer (U.S.) Business Overview
Table 103. Pfizer (U.S.) Recent Developments
Table 104. Sanofi Pasteur (France) Basic Information
Table 105. Sanofi Pasteur (France) Inactivated Vaccine Product Overview
Table 106. Sanofi Pasteur (France) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Sanofi Pasteur (France) Business Overview
Table 108. Sanofi Pasteur (France) Recent Developments
Table 109. Serum Institute of India Pvt (India) Basic Information
Table 110. Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
Table 111. Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Serum Institute of India Pvt (India) Business Overview
Table 113. Serum Institute of India Pvt (India) Recent Developments
Table 114. Global Inactivated Vaccine Sales Forecast by Region (2026-2033) & (K MT)
Table 115. Global Inactivated Vaccine Market Size Forecast by Region (2026-2033) & (M USD)
Table 116. North America Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 117. North America Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 118. Europe Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 119. Europe Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 120. Asia Pacific Inactivated Vaccine Sales Forecast by Region (2026-2033) & (K MT)
Table 121. Asia Pacific Inactivated Vaccine Market Size Forecast by Region (2026-2033) & (M USD)
Table 122. South America Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 123. South America Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 124. Middle East and Africa Inactivated Vaccine Sales Forecast by Country (2026-2033) & (Units)
Table 125. Middle East and Africa Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 126. Global Inactivated Vaccine Sales Forecast by Type (2026-2033) & (K MT)
Table 127. Global Inactivated Vaccine Market Size Forecast by Type (2026-2033) & (M USD)
Table 128. Global Inactivated Vaccine Price Forecast by Type (2026-2033) & (USD/KG)
Table 129. Global Inactivated Vaccine Sales (K MT) Forecast by Application (2026-2033)
Table 130. Global Inactivated Vaccine Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine Market Size Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Inactivated Vaccine Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Inactivated Vaccine Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2024)
Table 10. Global Market Inactivated Vaccine Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Inactivated Vaccine Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Inactivated Vaccine Sales by Type (K MT)
Table 26. Global Inactivated Vaccine Market Size by Type (M USD)
Table 27. Global Inactivated Vaccine Sales (K MT) by Type (2020-2025)
Table 28. Global Inactivated Vaccine Sales Market Share by Type (2020-2025)
Table 29. Global Inactivated Vaccine Market Size (M USD) by Type (2020-2025)
Table 30. Global Inactivated Vaccine Market Size Share by Type (2020-2025)
Table 31. Global Inactivated Vaccine Price (USD/KG) by Type (2020-2025)
Table 32. Global Inactivated Vaccine Sales (K MT) by Application
Table 33. Global Inactivated Vaccine Market Size by Application
Table 34. Global Inactivated Vaccine Sales by Application (2020-2025) & (K MT)
Table 35. Global Inactivated Vaccine Sales Market Share by Application (2020-2025)
Table 36. Global Inactivated Vaccine Market Size by Application (2020-2025) & (M USD)
Table 37. Global Inactivated Vaccine Market Share by Application (2020-2025)
Table 38. Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
Table 39. Global Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 40. Global Inactivated Vaccine Sales Market Share by Region (2020-2025)
Table 41. Global Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 42. Global Inactivated Vaccine Market Size Market Share by Region (2020-2025)
Table 43. North America Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 44. North America Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 46. Europe Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 49. South America Inactivated Vaccine Sales by Country (2020-2025) & (K MT)
Table 50. South America Inactivated Vaccine Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Inactivated Vaccine Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Inactivated Vaccine Market Size by Region (2020-2025) & (M USD)
Table 53. Global Inactivated Vaccine Production (K MT) by Region(2020-2025)
Table 54. Global Inactivated Vaccine Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Inactivated Vaccine Revenue Market Share by Region (2020-2025)
Table 56. Global Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Astellas Pharma (Japan) Basic Information
Table 62. Astellas Pharma (Japan) Inactivated Vaccine Product Overview
Table 63. Astellas Pharma (Japan) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Astellas Pharma (Japan) Business Overview
Table 65. Astellas Pharma (Japan) SWOT Analysis
Table 66. Astellas Pharma (Japan) Recent Developments
Table 67. CSL Limited (Australia) Basic Information
Table 68. CSL Limited (Australia) Inactivated Vaccine Product Overview
Table 69. CSL Limited (Australia) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. CSL Limited (Australia) Business Overview
Table 71. CSL Limited (Australia) SWOT Analysis
Table 72. CSL Limited (Australia) Recent Developments
Table 73. Emergent BioSolutions (U.S.) Basic Information
Table 74. Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
Table 75. Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Emergent BioSolutions (U.S.) Business Overview
Table 77. Emergent BioSolutions (U.S.) SWOT Analysis
Table 78. Emergent BioSolutions (U.S.) Recent Developments
Table 79. GlaxoSmithKline (U.K.) Basic Information
Table 80. GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
Table 81. GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. GlaxoSmithKline (U.K.) Business Overview
Table 83. GlaxoSmithKline (U.K.) Recent Developments
Table 84. Johnson and Johnson (U.S.) Basic Information
Table 85. Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
Table 86. Johnson and Johnson (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. Johnson and Johnson (U.S.) Business Overview
Table 88. Johnson and Johnson (U.S.) Recent Developments
Table 89. MedImmune (U.S.) Basic Information
Table 90. MedImmune (U.S.) Inactivated Vaccine Product Overview
Table 91. MedImmune (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. MedImmune (U.S.) Business Overview
Table 93. MedImmune (U.S.) Recent Developments
Table 94. Merck and Co (U.S.) Basic Information
Table 95. Merck and Co (U.S.) Inactivated Vaccine Product Overview
Table 96. Merck and Co (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Merck and Co (U.S.) Business Overview
Table 98. Merck and Co (U.S.) Recent Developments
Table 99. Pfizer (U.S.) Basic Information
Table 100. Pfizer (U.S.) Inactivated Vaccine Product Overview
Table 101. Pfizer (U.S.) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Pfizer (U.S.) Business Overview
Table 103. Pfizer (U.S.) Recent Developments
Table 104. Sanofi Pasteur (France) Basic Information
Table 105. Sanofi Pasteur (France) Inactivated Vaccine Product Overview
Table 106. Sanofi Pasteur (France) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Sanofi Pasteur (France) Business Overview
Table 108. Sanofi Pasteur (France) Recent Developments
Table 109. Serum Institute of India Pvt (India) Basic Information
Table 110. Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
Table 111. Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Serum Institute of India Pvt (India) Business Overview
Table 113. Serum Institute of India Pvt (India) Recent Developments
Table 114. Global Inactivated Vaccine Sales Forecast by Region (2026-2033) & (K MT)
Table 115. Global Inactivated Vaccine Market Size Forecast by Region (2026-2033) & (M USD)
Table 116. North America Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 117. North America Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 118. Europe Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 119. Europe Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 120. Asia Pacific Inactivated Vaccine Sales Forecast by Region (2026-2033) & (K MT)
Table 121. Asia Pacific Inactivated Vaccine Market Size Forecast by Region (2026-2033) & (M USD)
Table 122. South America Inactivated Vaccine Sales Forecast by Country (2026-2033) & (K MT)
Table 123. South America Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 124. Middle East and Africa Inactivated Vaccine Sales Forecast by Country (2026-2033) & (Units)
Table 125. Middle East and Africa Inactivated Vaccine Market Size Forecast by Country (2026-2033) & (M USD)
Table 126. Global Inactivated Vaccine Sales Forecast by Type (2026-2033) & (K MT)
Table 127. Global Inactivated Vaccine Market Size Forecast by Type (2026-2033) & (M USD)
Table 128. Global Inactivated Vaccine Price Forecast by Type (2026-2033) & (USD/KG)
Table 129. Global Inactivated Vaccine Sales (K MT) Forecast by Application (2026-2033)
Table 130. Global Inactivated Vaccine Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Inactivated Vaccine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine Market Size (M USD), 2024-2033
Figure 5. Global Inactivated Vaccine Market Size (M USD) (2020-2033)
Figure 6. Global Inactivated Vaccine Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Inactivated Vaccine Product Life Cycle
Figure 13. Inactivated Vaccine Sales Share by Manufacturers in 2024
Figure 14. Global Inactivated Vaccine Revenue Share by Manufacturers in 2024
Figure 15. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Inactivated Vaccine Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine Revenue in 2024
Figure 18. Industry Chain Map of Inactivated Vaccine
Figure 19. Global Inactivated Vaccine Market PEST Analysis
Figure 20. Global Inactivated Vaccine Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Inactivated Vaccine Market Share by Type
Figure 27. Sales Market Share of Inactivated Vaccine by Type (2020-2025)
Figure 28. Sales Market Share of Inactivated Vaccine by Type in 2024
Figure 29. Market Size Share of Inactivated Vaccine by Type (2020-2025)
Figure 30. Market Size Share of Inactivated Vaccine by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Inactivated Vaccine Market Share by Application
Figure 33. Global Inactivated Vaccine Sales Market Share by Application (2020-2025)
Figure 34. Global Inactivated Vaccine Sales Market Share by Application in 2024
Figure 35. Global Inactivated Vaccine Market Share by Application (2020-2025)
Figure 36. Global Inactivated Vaccine Market Share by Application in 2024
Figure 37. Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
Figure 38. Global Inactivated Vaccine Sales Market Share by Region (2020-2025)
Figure 39. Global Inactivated Vaccine Market Size Market Share by Region (2020-2025)
Figure 40. North America Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Inactivated Vaccine Sales Market Share by Country in 2024
Figure 43. North America Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 45. U.S. Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Inactivated Vaccine Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Inactivated Vaccine Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Inactivated Vaccine Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Inactivated Vaccine Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Inactivated Vaccine Sales Market Share by Country in 2024
Figure 53. Europe Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 55. Germany Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2024
Figure 67. Asia Pacific Inactivated Vaccine Market Size Market Share by Region in 2024
Figure 68. China Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 79. South America Inactivated Vaccine Sales Market Share by Country in 2024
Figure 80. South America Inactivated Vaccine Market Size and Growth Rate (M USD)
Figure 81. South America Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 82. Brazil Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Inactivated Vaccine Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Inactivated Vaccine Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Inactivated Vaccine Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Inactivated Vaccine Production Market Share by Region (2020-2025)
Figure 103. North America Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 106. China Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Inactivated Vaccine Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Inactivated Vaccine Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Inactivated Vaccine Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Inactivated Vaccine Market Share Forecast by Type (2026-2033)
Figure 111. Global Inactivated Vaccine Sales Forecast by Application (2026-2033)
Figure 112. Global Inactivated Vaccine Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Inactivated Vaccine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine Market Size (M USD), 2024-2033
Figure 5. Global Inactivated Vaccine Market Size (M USD) (2020-2033)
Figure 6. Global Inactivated Vaccine Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Inactivated Vaccine Product Life Cycle
Figure 13. Inactivated Vaccine Sales Share by Manufacturers in 2024
Figure 14. Global Inactivated Vaccine Revenue Share by Manufacturers in 2024
Figure 15. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Inactivated Vaccine Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine Revenue in 2024
Figure 18. Industry Chain Map of Inactivated Vaccine
Figure 19. Global Inactivated Vaccine Market PEST Analysis
Figure 20. Global Inactivated Vaccine Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Inactivated Vaccine Market Share by Type
Figure 27. Sales Market Share of Inactivated Vaccine by Type (2020-2025)
Figure 28. Sales Market Share of Inactivated Vaccine by Type in 2024
Figure 29. Market Size Share of Inactivated Vaccine by Type (2020-2025)
Figure 30. Market Size Share of Inactivated Vaccine by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Inactivated Vaccine Market Share by Application
Figure 33. Global Inactivated Vaccine Sales Market Share by Application (2020-2025)
Figure 34. Global Inactivated Vaccine Sales Market Share by Application in 2024
Figure 35. Global Inactivated Vaccine Market Share by Application (2020-2025)
Figure 36. Global Inactivated Vaccine Market Share by Application in 2024
Figure 37. Global Inactivated Vaccine Sales Growth Rate by Application (2020-2025)
Figure 38. Global Inactivated Vaccine Sales Market Share by Region (2020-2025)
Figure 39. Global Inactivated Vaccine Market Size Market Share by Region (2020-2025)
Figure 40. North America Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Inactivated Vaccine Sales Market Share by Country in 2024
Figure 43. North America Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 45. U.S. Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Inactivated Vaccine Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Inactivated Vaccine Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Inactivated Vaccine Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Inactivated Vaccine Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Inactivated Vaccine Sales Market Share by Country in 2024
Figure 53. Europe Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 55. Germany Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2024
Figure 67. Asia Pacific Inactivated Vaccine Market Size Market Share by Region in 2024
Figure 68. China Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 79. South America Inactivated Vaccine Sales Market Share by Country in 2024
Figure 80. South America Inactivated Vaccine Market Size and Growth Rate (M USD)
Figure 81. South America Inactivated Vaccine Market Size Market Share by Country in 2024
Figure 82. Brazil Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Inactivated Vaccine Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Inactivated Vaccine Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Inactivated Vaccine Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Inactivated Vaccine Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Inactivated Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Inactivated Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Inactivated Vaccine Production Market Share by Region (2020-2025)
Figure 103. North America Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 106. China Inactivated Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Inactivated Vaccine Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Inactivated Vaccine Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Inactivated Vaccine Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Inactivated Vaccine Market Share Forecast by Type (2026-2033)
Figure 111. Global Inactivated Vaccine Sales Forecast by Application (2026-2033)
Figure 112. Global Inactivated Vaccine Market Share Forecast by Application (2026-2033)
